Hypersensitivity to adrenomedullin in post-traumatic headache: a randomized crossover study
In brief
Adrenomedullin triggered migraine-like headache in 81%, versus 19% on placebo
In a randomized crossover study of 21 adults with persistent post-traumatic headache and no pre-injury migraine, 17 developed migraine-like headache after adrenomedullin infusion, compared with four after placebo. Headaches also began sooner after adrenomedullin, but the small, single-center study needs confirmation before this pathway can guide treatment.
- Journal
- Brain : a journal of neurology (Q1)
- Published
- 13 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Haidar M Al-Khazali, Zahra Hakimzadeh, Anna G Melchior, Berkay Alpay, Ksenija Cucanić, Annette M Fuchs, et al.
- PMID
- 43021468
- DOI
- 10.1093/brain/awag401
Why clinicians should know about it
- Picked for Neurology (clinical) (top studies of the week, 15 November 2026): Randomized crossover study of headache mechanisms in persistent post-traumatic headache
Abstract
Adrenomedullin (ADM), a vasoactive member of the calcitonin peptide family with receptor-signalling overlap with calcitonin gene-related peptide (CGRP), has emerged as a candidate therapeutic target in migraine. Given the striking clinical parallels between migraine and persistent post-traumatic headache (PTH), we investigated whether ADM-responsive signalling contributes to migraine-like headache in adults with persistent PTH attributed to mild traumatic brain injury. We conducted a single-centre, randomised, double-blind, placebo-controlled, two-way crossover study in adults with persistent PTH and no pre-trauma history of migraine. On two experimental days separated by at least 7 days, participants received 20-minute intravenous infusions of ADM (19.9 pmol kg⁻¹ min⁻¹) and isotonic saline as the matched inactive comparator (placebo) in randomised sequence. Headache outcomes were recorded for 12 hours. The primary outcome was the within-participant incidence of experimentally induced migraine-like headache. The secondary outcome was the within-participant difference in baseline-corrected area under the curve (AUC) for headache intensity from 0 to 12 hours. Of 158 individuals assessed for eligibility, 21 were randomised, completed both periods and were analysed. Participants had a mean age of 34.3 years, 19 (90%) were female, and 18 (86%) reported a migraine-like phenotype. Migraine-like headache occurred in 17 of 21 participants (81%) after ADM and four of 21 (19%) following placebo. Fourteen participants developed migraine-like only after ADM and one only following placebo, yielding a paired absolute risk difference of 61.9 percentage points (95% CI 29.7-80.6; one-sided P < 0.001; two-sided P = 0.001). Baseline-corrected headache-intensity AUC was higher after ADM than placebo (median 1,110 [IQR 315-2205] versus 420 [-160 to 565]; P = 0.006). Median time to onset of migraine-like headache was 30 minutes after ADM and 390 minutes following placebo. Fifteen participants reported that the ADM-induced headache resembled their usual migraine-like headache episodes, and rescue medication was used by 10 participants after ADM and two after placebo. These findings identify pronounced responsiveness to ADM-linked signalling in persistent PTH and support the ADM pathway as a candidate target for mechanism-based therapeutic development, pending confirmation in independent cohorts and complementary preclinical studies.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.